| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | -0.16 | 0.001 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.091 | 0.003 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.003 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | -0.15 | 0.003 |
| mRNA | niclosamide | CTRPv2 | pan-cancer | AAC | 0.1 | 0.004 |
| mRNA | GNF-2 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.004 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.005 |